Противовирусная активность энисамия йодида в отношении вирусов гриппа и ОРВИ in vitro на различных клеточных линиях - Журнал Терапевтический архив №11 Инфекционные болезни 2020
Противовирусная активность энисамия йодида в отношении вирусов гриппа и ОРВИ in vitro на различных клеточных линиях
Зарубаев В.В., Слита А.В., Синегубова Е.О. и др. Противовирусная активность энисамия йодида в отношении вирусов гриппа и ОРВИ in vitro на различных клеточных линиях. Терапевтический архив. 2020; 92 (11): 45–50.
DOI: 10.26442/00403660.2020.11.000872
DOI: 10.26442/00403660.2020.11.000872
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Грипп и острая респираторная вирусная инфекция представляют наиболее многочисленную и опасную группу возбудителей респираторных инфекций человека.
Цель. Характеристика противовирусных свойств энисамия йодида в отношении респираторных вирусов человека в экспериментах in vitro.
Материалы и методы. В ходе экспериментов изучены цитотоксические свойства энисамия йодида в отношении линий Vero, MA-104, A549, L-41 и HEp-2. Противовирусная активность энисамия йодида исследована при помощи теста на снижение вирусного титра в отношении вирусов гриппа, парагриппа, респираторно-синцитиального вируса, вирусов Коксаки B3 и B4, а также аденовирусов 5 и 6-го типов.
Результаты. Наиболее чувствительным к действию энисамия йодида оказался вирус парагриппа человека, активность которого под действием препарата снижалась в клетках A549 на 2,3 порядка. Из использованных клеточных культур максимальный противовирусный эффект энисамия йодид проявлял в клетках карциномы легкого человека A549, где в его присутствии на порядок и больше снижался уровень репродукции аденовирусов 5 и 6-го типов, вирусов Коксаки B3 и B4 и вируса парагриппа человека.
В наименьшей степени противовирусная активность энисамия йодида проявлялась в клетках Vero.
Заключение. По результатам опытов in vitro энисамия йодид можно рассматривать как противовирусный препарат широкого спектра активности в отношении респираторных вирусов человека.
Ключевые слова: энисамия йодид, противовирусная активность, грипп, острая респираторная вирусная инфекция, непермиссивные клеточные линии.
Aim. Characterization of the antiviral properties of enisamium iodide against human respiratory viruses in in vitro experiments.
Materials and methods. In the course of experiments, the cytotoxic properties of enisamium iodide were studied against the cell lines Vero, MA-104, A549, L-41 and HEp-2. The antiviral activity of enisamium iodide was studied using virus yield reduction assay against influenza viruses, parainfluenza virus, respiratory syncytial virus, Coxsackie B3 and Coxsackie B4 viruses, as well as adenoviruses types 5 and 6.
Results. The most sensitive to the action of enisamium iodide was the human parainfluenza virus, whose activity decreased by 2.3 orders of magnitude under the action of the drug in A549 cells. Of the cell cultures used, enisamium iodide exhibited the maximum antiviral effect in human lung carcinoma cells A549, where, in its presence, the level of reproduction of adenoviruses of types 5 and 6, Coxsackie viruses B3 and B4, and human parainfluenza virus decreased by an order of magnitude or more. The antiviral activity of enisamium iodide was least manifested in Vero cells.
Conclusion. According to the results of in vitro experiments, enisamium iodide can be considered as an antiviral drug with a wide spectrum of activity against human respiratory viruses.
Keywords: enisamium iodide, anti-viral activity, influenza, ARVI, non-permissive cell lines.
Цель. Характеристика противовирусных свойств энисамия йодида в отношении респираторных вирусов человека в экспериментах in vitro.
Материалы и методы. В ходе экспериментов изучены цитотоксические свойства энисамия йодида в отношении линий Vero, MA-104, A549, L-41 и HEp-2. Противовирусная активность энисамия йодида исследована при помощи теста на снижение вирусного титра в отношении вирусов гриппа, парагриппа, респираторно-синцитиального вируса, вирусов Коксаки B3 и B4, а также аденовирусов 5 и 6-го типов.
Результаты. Наиболее чувствительным к действию энисамия йодида оказался вирус парагриппа человека, активность которого под действием препарата снижалась в клетках A549 на 2,3 порядка. Из использованных клеточных культур максимальный противовирусный эффект энисамия йодид проявлял в клетках карциномы легкого человека A549, где в его присутствии на порядок и больше снижался уровень репродукции аденовирусов 5 и 6-го типов, вирусов Коксаки B3 и B4 и вируса парагриппа человека.
В наименьшей степени противовирусная активность энисамия йодида проявлялась в клетках Vero.
Заключение. По результатам опытов in vitro энисамия йодид можно рассматривать как противовирусный препарат широкого спектра активности в отношении респираторных вирусов человека.
Ключевые слова: энисамия йодид, противовирусная активность, грипп, острая респираторная вирусная инфекция, непермиссивные клеточные линии.
________________________________________________
Aim. Characterization of the antiviral properties of enisamium iodide against human respiratory viruses in in vitro experiments.
Materials and methods. In the course of experiments, the cytotoxic properties of enisamium iodide were studied against the cell lines Vero, MA-104, A549, L-41 and HEp-2. The antiviral activity of enisamium iodide was studied using virus yield reduction assay against influenza viruses, parainfluenza virus, respiratory syncytial virus, Coxsackie B3 and Coxsackie B4 viruses, as well as adenoviruses types 5 and 6.
Results. The most sensitive to the action of enisamium iodide was the human parainfluenza virus, whose activity decreased by 2.3 orders of magnitude under the action of the drug in A549 cells. Of the cell cultures used, enisamium iodide exhibited the maximum antiviral effect in human lung carcinoma cells A549, where, in its presence, the level of reproduction of adenoviruses of types 5 and 6, Coxsackie viruses B3 and B4, and human parainfluenza virus decreased by an order of magnitude or more. The antiviral activity of enisamium iodide was least manifested in Vero cells.
Conclusion. According to the results of in vitro experiments, enisamium iodide can be considered as an antiviral drug with a wide spectrum of activity against human respiratory viruses.
Keywords: enisamium iodide, anti-viral activity, influenza, ARVI, non-permissive cell lines.
Список литературы
1. Ruuskanen O, Meurman O, Sarkkinen H. Adenoviral diseases in children: a study of 105 cases. Pediatrics. 1985;76:79-83.
2. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98:174-85. doi: 10.1016/j.antiviral.2013.03.014
3. Steel J, Lowen AC. Influenza A virus reassortment. Curr Top Microbiol Immunol. 2014;385:377-401. doi: 10.1007/82_2014_395
4. Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242-64.
5. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264-75.
6. Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol. Immunol. 1984;110:191-220.
7. Erdman DD, Xu W, Gerber SI, et al. Molecular epidemiology of adenovirus type 7 in the United States, 1966–2000. Emerg Infect Dis. 2002;8:269-77.
8. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1997;27:1197-200.
9. Azbug MJ, Levin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics. 1991;87:890-6.
10. Rosario RF, Kimbrough RC, Van Buren DH, Laski ME. Fatal adenovirus serotype-5 in a deceased-donor renal transplant recipient. Transpl Infect Dis. 2006;8(1):54-7.
11. Abarca VK, Le Corre PN, Perret PC, et al. Disseminated and fatal adenovirus infection in an immunocompromised child. Rev Chilena Infectol. 2008;25(2):127-32.
12. Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. doi: 10.1177/2040206618811416
13. Hume A, Mühlberger E. Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner J Infect Dis. 2018;218(Suppl_5):S403-S408. doi: 10.1093/infdis/jiy473
14. Zurney J, Howard KE, Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol. 2007;81(24):13668-80. doi: 10.1128/JVI.01172-07
15. Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol. 2005;79(20):12944-51. doi: 10.1128/JVI.79.20.12944-12951.2005
16. Goutagny N, Jiang Z, Tian J, et al. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol. 2010;184(3):1168-79. doi: 10.4049/jimmunol.0902750
17. Mesa B. The Effect of Cell Type on the Efficacy of CMV Antiviral Drugs. Virginia Commonwealth University, 2008.
18. Chung D. The Establishment of an Antiviral State by Pyrimidine Synthesis Inhibitor is Cell Type-Specific. J Antimicrob Agents. 2015;1(1):101.
19. Cocking D, Cinatl J, Boltz DA, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 2018;62(2):191-5. doi: 10.4149/av_2018_211
20. Haltner-Ukomadu E, Gureyeva S, Burmaka O, et al. In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Pharm. 2018;86(1):3. doi: 10.3390/scipharm86010003
21. Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol. 1986 Jun;6(6):2279-83. doi: 10.1128/mcb.6.6.2279
22. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43(1):247-52. doi: 10.1099/0022-1317-43-1-247
2. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98:174-85. doi: 10.1016/j.antiviral.2013.03.014
3. Steel J, Lowen AC. Influenza A virus reassortment. Curr Top Microbiol Immunol. 2014;385:377-401. doi: 10.1007/82_2014_395
4. Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242-64.
5. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264-75.
6. Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol. Immunol. 1984;110:191-220.
7. Erdman DD, Xu W, Gerber SI, et al. Molecular epidemiology of adenovirus type 7 in the United States, 1966–2000. Emerg Infect Dis. 2002;8:269-77.
8. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1997;27:1197-200.
9. Azbug MJ, Levin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics. 1991;87:890-6.
10. Rosario RF, Kimbrough RC, Van Buren DH, Laski ME. Fatal adenovirus serotype-5 in a deceased-donor renal transplant recipient. Transpl Infect Dis. 2006;8(1):54-7.
11. Abarca VK, Le Corre PN, Perret PC, et al. Disseminated and fatal adenovirus infection in an immunocompromised child. Rev Chilena Infectol. 2008;25(2):127-32.
12. Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. doi: 10.1177/2040206618811416
13. Hume A, Mühlberger E. Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner J Infect Dis. 2018;218(Suppl_5):S403-S408. doi: 10.1093/infdis/jiy473
14. Zurney J, Howard KE, Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol. 2007;81(24):13668-80. doi: 10.1128/JVI.01172-07
15. Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol. 2005;79(20):12944-51. doi: 10.1128/JVI.79.20.12944-12951.2005
16. Goutagny N, Jiang Z, Tian J, et al. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol. 2010;184(3):1168-79. doi: 10.4049/jimmunol.0902750
17. Mesa B. The Effect of Cell Type on the Efficacy of CMV Antiviral Drugs. Virginia Commonwealth University, 2008.
18. Chung D. The Establishment of an Antiviral State by Pyrimidine Synthesis Inhibitor is Cell Type-Specific. J Antimicrob Agents. 2015;1(1):101.
19. Cocking D, Cinatl J, Boltz DA, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 2018;62(2):191-5. doi: 10.4149/av_2018_211
20. Haltner-Ukomadu E, Gureyeva S, Burmaka O, et al. In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Pharm. 2018;86(1):3. doi: 10.3390/scipharm86010003
21. Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol. 1986 Jun;6(6):2279-83. doi: 10.1128/mcb.6.6.2279
22. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43(1):247-52. doi: 10.1099/0022-1317-43-1-247
2. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98:174-85. doi: 10.1016/j.antiviral.2013.03.014
3. Steel J, Lowen AC. Influenza A virus reassortment. Curr Top Microbiol Immunol. 2014;385:377-401. doi: 10.1007/82_2014_395
4. Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242-64.
5. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264-75.
6. Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol. Immunol. 1984;110:191-220.
7. Erdman DD, Xu W, Gerber SI, et al. Molecular epidemiology of adenovirus type 7 in the United States, 1966–2000. Emerg Infect Dis. 2002;8:269-77.
8. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1997;27:1197-200.
9. Azbug MJ, Levin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics. 1991;87:890-6.
10. Rosario RF, Kimbrough RC, Van Buren DH, Laski ME. Fatal adenovirus serotype-5 in a deceased-donor renal transplant recipient. Transpl Infect Dis. 2006;8(1):54-7.
11. Abarca VK, Le Corre PN, Perret PC, et al. Disseminated and fatal adenovirus infection in an immunocompromised child. Rev Chilena Infectol. 2008;25(2):127-32.
12. Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. doi: 10.1177/2040206618811416
13. Hume A, Mühlberger E. Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner J Infect Dis. 2018;218(Suppl_5):S403-S408. doi: 10.1093/infdis/jiy473
14. Zurney J, Howard KE, Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol. 2007;81(24):13668-80. doi: 10.1128/JVI.01172-07
15. Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol. 2005;79(20):12944-51. doi: 10.1128/JVI.79.20.12944-12951.2005
16. Goutagny N, Jiang Z, Tian J, et al. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol. 2010;184(3):1168-79. doi: 10.4049/jimmunol.0902750
17. Mesa B. The Effect of Cell Type on the Efficacy of CMV Antiviral Drugs. Virginia Commonwealth University, 2008.
18. Chung D. The Establishment of an Antiviral State by Pyrimidine Synthesis Inhibitor is Cell Type-Specific. J Antimicrob Agents. 2015;1(1):101.
19. Cocking D, Cinatl J, Boltz DA, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 2018;62(2):191-5. doi: 10.4149/av_2018_211
20. Haltner-Ukomadu E, Gureyeva S, Burmaka O, et al. In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Pharm. 2018;86(1):3. doi: 10.3390/scipharm86010003
21. Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol. 1986 Jun;6(6):2279-83. doi: 10.1128/mcb.6.6.2279
22. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43(1):247-52. doi: 10.1099/0022-1317-43-1-247
________________________________________________
2. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98:174-85. doi: 10.1016/j.antiviral.2013.03.014
3. Steel J, Lowen AC. Influenza A virus reassortment. Curr Top Microbiol Immunol. 2014;385:377-401. doi: 10.1007/82_2014_395
4. Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242-64.
5. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264-75.
6. Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol. Immunol. 1984;110:191-220.
7. Erdman DD, Xu W, Gerber SI, et al. Molecular epidemiology of adenovirus type 7 in the United States, 1966–2000. Emerg Infect Dis. 2002;8:269-77.
8. Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1997;27:1197-200.
9. Azbug MJ, Levin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics. 1991;87:890-6.
10. Rosario RF, Kimbrough RC, Van Buren DH, Laski ME. Fatal adenovirus serotype-5 in a deceased-donor renal transplant recipient. Transpl Infect Dis. 2006;8(1):54-7.
11. Abarca VK, Le Corre PN, Perret PC, et al. Disseminated and fatal adenovirus infection in an immunocompromised child. Rev Chilena Infectol. 2008;25(2):127-32.
12. Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. doi: 10.1177/2040206618811416
13. Hume A, Mühlberger E. Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner J Infect Dis. 2018;218(Suppl_5):S403-S408. doi: 10.1093/infdis/jiy473
14. Zurney J, Howard KE, Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol. 2007;81(24):13668-80. doi: 10.1128/JVI.01172-07
15. Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol. 2005;79(20):12944-51. doi: 10.1128/JVI.79.20.12944-12951.2005
16. Goutagny N, Jiang Z, Tian J, et al. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol. 2010;184(3):1168-79. doi: 10.4049/jimmunol.0902750
17. Mesa B. The Effect of Cell Type on the Efficacy of CMV Antiviral Drugs. Virginia Commonwealth University, 2008.
18. Chung D. The Establishment of an Antiviral State by Pyrimidine Synthesis Inhibitor is Cell Type-Specific. J Antimicrob Agents. 2015;1(1):101.
19. Cocking D, Cinatl J, Boltz DA, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 2018;62(2):191-5. doi: 10.4149/av_2018_211
20. Haltner-Ukomadu E, Gureyeva S, Burmaka O, et al. In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Pharm. 2018;86(1):3. doi: 10.3390/scipharm86010003
21. Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol. 1986 Jun;6(6):2279-83. doi: 10.1128/mcb.6.6.2279
22. Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43(1):247-52. doi: 10.1099/0022-1317-43-1-247
Авторы
В.В. Зарубаев, А.В. Слита, Е.О. Синегубова, А.А. Мурылева, И.Н. Лаврентьева
ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Роспотребнадзора, Санкт-Петербург, Россия
Saint Petersburg Pasteur Institute, Saint Petersburg, Russia
ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Роспотребнадзора, Санкт-Петербург, Россия
________________________________________________
Saint Petersburg Pasteur Institute, Saint Petersburg, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.